Skip to main content

Can clinician champions reduce potentially inappropriate medications in people living with dementia? Study protocol for a cluster randomized trial



For people living with dementia (PLWD) the overuse of potentially inappropriate medications (PIMs) remains a persistent problem. De-prescribing trials in the elderly have mixed results. Clinician champions may be uniquely suited to lead efforts to address this challenge. Here we describe the study protocol for a 24-month embedded pragmatic cluster-randomized clinical trial within two accountable care organizations (ACOs) of such a clinician champion intervention. The specific aims are to (1) assess the effectiveness of a clinician champion on de-implementing PIMs in PLWD, (2) determine if the intervention is associated with a reduction in emergency department (ED) visits and hospitalizations attributed to a fall, and (3) examine five implementation outcomes: appropriateness, feasibility, fidelity, penetration, and equity.


Two ACOs agreed to participate: United States Medical Management (USMM) and Oschner Health System. The unit of randomization will be the primary care clinic. A clinician champion will be recruited from each of the intervention clinics to participate in a 6-month training program and then work with clinicians and staff in their clinic for 12 months to reduce the use of PIMs in their PLWD population. For aims 1 and 2, Medicare claims data will be used to assess outcomes. The outcome for aim #1 will be medication possession rates per quarter, for the three therapeutic classes of PIMs among patients with dementia in intervention clinics versus control clinics. For aim #2, we will assess the incidence of falls using a previously validated algorithm. For both aims 1 and 2, we will construct hierarchical models with time period observations nested within patient using generalized estimating equations (GEE) with robust standard errors. The key variable of interest will be the treatment indicator assigned based on practice. For aim #3, we will conduct qualitative thematic analysis of documentation by the clinician champions in their project workbooks to evaluate the five implementation outcomes.


This embedded pragmatic trial will add to our existing knowledge regarding the effectiveness of a clinician champion strategy to de-prescribe potentially inappropriate medication among patients with dementia as well as its appropriateness, feasibility, fidelity, penetration, and equity.

Trial registration

Clinicaltrials.govNCT05359679, Registered May 4, 2022

Peer Review reports


For people living with dementia (PLWD), the overuse of potentially inappropriate medications (PIMs), those for which the potential for harm outweighs benefit, remains a persistent problem despite evidence-based guidelines supporting their de-adoption [1,2,3]. These harms can include falls, cognitive impairment, hospital admission, functional impairment, and death. A group of geriatric experts convened by the Choosing Wisely initiative identified three classes of PIMs for PLWD: antipsychotics, benzodiazepines, and hypoglycemics (sulfonylureas and insulin) with adequate glycemic control [3, 4]. Here, we describe the study protocol for a 24-month embedded pragmatic cluster-randomized clinical trial within two large accountable care organizations (ACOs) of a clinician champion intervention to decrease the use of PIMs in PLWD funded by the National Institute of Aging’s IMbedded Pragmatic Alzheimer’s disease (AD) and AD-Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory [5].

The reported prevalence of any PIM when cognitive impairment is reported ranges from 20.6 to 80.5% [3]. Approximately 14.3% of Medicare Part D enrollees with dementia residing in the general community are prescribed an antipsychotic [6]. The prevalence of potentially inappropriate benzodiazepine prescriptions has been reported to be as high as 20% among elderly persons with dementia living in the community [7]. Another study found that the proportion of elderly patients with an A1c < 7% who received a prescription for sulfonylurea, insulin or combined insulin and sulfonylurea therapies was 35.2%, 24.2%, and 16.3% respectively and was as prevalent in those with dementia as in those without [8]. A study of comparing rates of PIM prescribing in traditional Medicare and Medicare Advantage populations from 2006-2015 found no difference in rates between the two groups [9]. In addition, there was no evidence of any decline in rates of prescribing over time. Given these findings, what can a health system do to de-implement PIMs among their PLWD population?

De-prescribing trials, either with the elderly or specific to patients with dementia, have mixed results [10,11,12,13,14,15,16]. The EMPOWER trial demonstrated that pharmacist-led shared decision-making conversations led to a significant reduction in inappropriate benzodiazepine use among community-dwelling older adults [17]. In the D-PRESCRIBE trial, a pharmacist led educational outreach intervention to both patients and their primary care clinician resulted in a significant decrease in the use of potentially inappropriate medications in a community-dwelling population of older adults [18]. However, the recently published OPTIMIZE trial reported no significant changes in numbers of long-term medications or number of PIMs after a light-touch educational de-prescribing intervention for older adults with cognitive impairment taking 5 or more long-term medications and their primary care clinicians [19].

Developing and supporting a clinician champion is a simple and pragmatic implementation strategy that might be effective in addressing the overuse of PIMs in the PLWD population. Factors affecting de-implementation are multi-level, complex, context specific, and interact in ways that are different than implementation of an evidence-based service [20]. There is a clear rationale for why clinician champions are uniquely suited to lead a multi-level context-specific de-implementation change effort [21]. They are front-line clinicians who can advocate for and influence practice-driven change and may be particularly effective in de-implementing PIMs because they can (1) be a trusted source of information for colleagues and patients about the potential harms of PIMs, (2) provide feedback and discuss prescribing behaviors with their colleagues, (3) serve as a role model for how to provide guideline-concordant care for PLWD [22], and (4) identify practice-specific barriers and facilitators and leverage them to reduce PIMs use in their local setting [23]. Use of a clinician champion is widely recognized as effective in implementing evidence-based practices in health care settings [21]. Less is known about their effectiveness in de-implementing a low-value service such as PIMs among PLWD [24].

With support from the Robert Wood Johnson Foundation, (RWJF) six clinician champions from safety net care settings across the USA recently completed a fellowship training program to provide them with the core competencies they needed to be effective in reducing an overused service in their setting. A group of national experts with experience in de-implementing low-value care served as faculty. Work by these value champions resulted in declines in the use of triple lumen peripherally inserted central venous lines in the inpatient setting, imaging for low back pain in the emergency department, prescribed cough and cold medicines for infants and children in a primary care setting and prescribing long-term opioids for patients with chronic pain. The six most important implementation strategies used by the champions to support de-implementation were building a coalition of partners in the effort, conducting a local needs assessment, developing a formal implementation blueprint, conducting educational meetings, facilitating conversations about the overused service, and implementing clinical reminders [25]. A formative and summative evaluation of the Fellowship resulted in the development of a training curriculum and a project workbook to guide the work of a clinician champion during a low-value care project.

For this study clinician champions will participate in training using the RWJF fellowship curriculum and lead an initiative within their primary care clinic setting to decrease the use of the three classes of PIMs described above for PLWD: antipsychotics, benzodiazepines and hypoglycemic medications. The specific aims are to (1) assess the effectiveness of a clinician champion on de-implementing these three classes of PIMs, (2) determine if the intervention is associated with a reduction in emergency department (ED) visits and hospitalizations attributed to a fall, and (3) examine five implementation outcomes critical to the success of the de-implementation effort: appropriateness, feasibility, fidelity, penetration, and equity.


Settings, subjects, and recruitment

Accountable Care Organizations (ACOs) are designed to promote patient-centered care and reduce the use of unnecessary services, making them a natural setting to test the effectiveness of a clinician value champion intervention. Co-investigators with the Institute for Accountable Care (IAC), which is the research arm of the National Association of Accountable Care Organizations, (NAACOS), worked with NAACOS to recruit two ACOs for this study: United States Medical Management (USMM) and Oschner Health System. Clinicians with the Visiting Physicians Association contract with USMM to conduct home-based primary care from 39 offices across 13 states. Teams in each office consists of a provider/medical assistant dyad who is also supported by a patient care coordinator, a scheduler, and a nurse navigator who does outreach to more complex patients. Within each office, a medical team meets weekly to discuss patient cases and update their approach to patient care. Over 30% of the Medicare population they served in 2019 (approximately 6000 patients) had an established diagnosis of dementia (Table 1). Oschner Health System is in Louisiana and has 28 primary care clinic locations within their integrated group practice. Their Medicare ACO population had 31,525 enrollees in 2019 and within this population 1387 (4.4%) had a documented diagnosis of dementia (Table 1).

Table 1 Medicare beneficiaries with dementia in each accountable care organization


A schedule of enrollment, randomization and allocation, interventions, and assessments for the study is found in Table 2. The unit of randomization will be the primary care clinic, and outcomes for aims 1 and 2 will be assessed by comparing patients with a diagnosis of dementia who receive care in clinics assigned to the intervention arm to those who receive care in clinics assigned to the control arm of the study. We anticipate 32 out of 39 teams from USMM to meet eligibility and 26 out of 28 practices for Ochsner Health. Within each ACO, we will randomly select half of the practices for the intervention and the remaining practices will continue with usual care as controls. Prior to random assignment, we will stratify practices based on size using data for 2019–2020. Practices will be paired by number of unique beneficiaries treated (first and second largest practice, third and fourth largest, and so on) and then one member of each pair will be randomly selected via a random number generator to be a treatment site. Once randomized, a clinician champion will be recruited from each of the offices or clinics in the intervention arm of the study in partnership with the ACO leadership to participate in the clinician champion training program. Neither investigators nor participants will be blinded to allocation. The random allocation sequence and assignment to study arms will be done by the statistician (GR) at Brandeis University.

Table 2 Schedule of enrollment, interventions, and assessments


Each clinician champion will participate in one-hour training webinars over 6 months (January–June 2022) using the curriculum developed in the afore-mentioned RWJF Value Champions fellowship program. These sessions will be led by the PI (MP) who also was the Director of the RWJF value champion fellowship from which these materials were developed. The Learning Modules (Table 3) follow the same format and include a rationale, quotes from RWJF value champion fellows, learning objectives, required readings, discussion questions, application of the learnings to their project workbook, and additional resources. Each Learning Module is also accompanied by a Facilitator/Instructors Guide so that any health care organization can use these materials to train their own value champions. Near the end of the training webinars, each value champion will launch his/her own 12-month PIM de-prescribing project (April 2022–March 2023) using the Project Workbook as their guide. Following the 6 months of training clinician champions will participate in a monthly 1-h shared learning webinar to share successes, challenges, and brainstorm solutions during the 12 months when champions are doing the work to support reductions in the use of PIMs in PLWD.

Table 3 Value champion learning modules

Data sources and collection

For aims 1 and 2, de-identified Medicare claims data will be used to assess outcomes. Co-investigators from the Institute for Accountable Care (IAC) will access Medicare claims data in the CMS Virtual Research Data Center (VRDC) repository and claims provided to ACOs (Claim and Claim Line Feed File or CCLF files). Specifically, we will use quarterly Medicare clinician bills (Part B), institutional bills (Part A), and prescription drug event (PDE) data (Part D) for diagnostic and utilization information on Medicare beneficiaries and practices for 2019 and 2020. Data for 2021 and 2022, including prescription drug events data, clinician bills and institutional bills will be derived from the ACO’s CCLF files which are provided by CMS monthly. For aim #3, the five implementation outcomes will be assessed by using available project management data recorded by each value champion in their project workbook, specifically the milestones completed within and across each phase of work outlined in the workbook.

Following an intent-to-treat design, all Medicare beneficiaries meeting our dementia eligibility criteria will be included in the study, regardless of level of engagement with practice clinicians. Specific criteria include the following:

  1. 1.

    Assigned to one of the participating ACO during the study period;

  2. 2.

    Continuously enrolled in Medicare Parts A, B, and D;

  3. 3.

    Have dementia as defined in Medicare claims data using the Bynum-Standard algorithm [26]; and

  4. 4.

    Have one or more evaluation and management visit at a participating practice during the study period.

Medicare beneficiaries will be excluded if they have any months of Part C (Medicare Advantage) during study period since prevents us from seeing all of their care. All data will be available to all study investigators.

Data analysis

Specific aim #1 analysis

The primary outcome for this study will be medication possession rates (MPR) per quarter, for the three therapeutic classes of PIMs. These beneficiary-level measures are calculated as quotients with denominator equal to the length of the quarter and the numerators equal to the days supplied for prescriptions within the class filled during the quarter, plus excess days-supply from the previous period minus excess days-supply remaining at the end [27]. Overlapping prescriptions from within the same therapeutic class will be only counted once. Unlike many studies using medication possession rates to exam adherence, we are interested in reducing, not increasing, the percent of days covered. We will initially try to model the originally valued MPR variables, but may have to transform the scores to ordinal variables based on the ‘degree’ of deprescribing. For example, Benner and colleagues in their study of statin adherence defined non-adherence as MPRs within 0–20%, low adherence as between 21 and 79% and high adherence as 80% or higher [28]. In addition to MPRs, we will also calculate and model the number of 30-day prescriptions per time period for each beneficiary in the study.

Data analysis will begin with descriptive statistics, comparing the mix of patients at each practice including demographics, chronic conditions, and incident versus prevalent dementia. This will allow us to check for balance between treatment and control practices and inform subsequent modeling. To determine the impact of the intervention, we will construct hierarchical models with time period observations nested within patient. These models will be random effects or generalized estimating equations (GEE) with robust standard errors, and will be either linear, if original MPRs are used as outcome, or generalized linear, if transformation necessary. The key variable of interest in these models will be the treatment indicator (assigned based on practice). Since there could well be a time effect of treatment, we will explore several model specifications, such as discrete indicators for the time periods or a single continuous variable. Interactions of treatment with time period will also be explored. By examining various different specifications involving time, we should be able to determine whether the intervention leads to a one-time change, a gradual trend over time, or a combination of both (an immediate jump with a further change, as time passes). Finally, we will explore the impact of this intervention on health inequities by stratifying our primary analysis by race/ethnicity using indicators from the Medicare beneficiary summary file (MBSF).

As a secondary outcome (aim #2), we will assess the incidence of falls during the study window using an algorithm developed by Min and colleagues [29]. Specifically, the measure looks for direct indicators of fall (e.g., ‘reason for visit’ codes) or the presence of injuries most likely caused by a fall (spiral fracture to the radius) on all provider (part B) and institutional (part A) claims. Key covariates in all of our regression models will include age and sex, and reason for entitlement since these may be out of balance given the small number of practices being randomized. We will also include a fixed effect for ACO.

For specific aim #3, we will have a total of 30 clinician value champions across the 2 ACOs who will share their completed project workbooks to assess the five implementation outcomes. Current approaches to evaluating implementation outcomes are still nascent, with few measures that have validated psychometric properties [30, 31]. We will report each outcome, for example, the number of feasibility milestones completed, as an overall proportion or their central tendency such as a mean value with standard deviation, both within each ACO and across the two ACOs. Conceptually, these measures are inter-dependent, and are connected with service outcomes, such as patient safety, measured here by exposure to a PIM within our study population of PLWD [32]. In addition, notes and recordings from monthly shared learning calls will be used to conduct a thematic analysis using a deductive approach using the five outcomes described in Table 4 [33].

Table 4 Implementation outcomes

Workbook data will also be used to understand their activities as documented in their responses to journal question prompts and assess their fidelity to the intervention by examining the proportion of milestones reached for each phase of their work as documented in the workbook [33]. If the workbook data and notes and recordings from monthly shared learning calls prove to be inadequate, we will conduct structured interviews with a sub-set of clinician champions near the end of the intervention period to identify their activities, assess fidelity, and evaluate implementation outcomes.

Sample size and power

Our sampling plan anticipates enrolling at least 30 of the 39 practices in USMM and 26 of the 28 practices in Ochsner. Based on Medicare enrollments of 39,000 members in USMM with a 20% dementia rate in 2019, and 10,000 members in Ochsner with approximately 10% of members diagnosed with dementia om 2019, we should have at least 2000 patients per treatment group for USMM and 500 patients per treatment group for Ochsner. For our primary outcome, with a follow-up period of 1 year and with mediation possession rates calculated per patient each quarter, we will have approximately 4 MPR observations per patient or 8000 observations per group for USMM analyses and 2000 per group for Ochsner. Even after assuming significant correlation across time within patient and modest correlation between patients within a practice, which will reduce effective sample sizes by 20%, we should have the equivalent of 6400 observations per treatment group for our USMM analyses and 1600 observations per treatment group for Ochsner. The expectation of our intervention is that for each medication class, it will produce clinically relevant decreases in mean possession rates of 10% of a standard deviation. If the effect size is this large for a medication class and using a 5% level of significance, our Ochsner sample (with effective size of at least 1600 per group) will have 80% power to discern a significant difference, while our larger USMM sample (with effective size of at least 6400 per group) will have almost 100% power. Indeed, our USMM sample will have 80% power to find a significant difference, even if the effect size is only 5% of a standard deviation. Ethics approval for this study was obtained through the IMPACT Collaboratory’s central institutional review board, Advarra, on September 8, 2021.

Data monitoring

The NIA IMPACT Collaboratory’s Data Safety Monitoring Board will provide oversight and review. The data safety monitoring plan includes monthly adverse event reporting by each clinician champion for patients with dementia seen in clinics randomized to the intervention arm. All adverse events that are serious and unexpected will be reported to the IMPACT Collaboratory Regulatory and Data Team Leader, NIA IMPACT Collaboratory Project Officer, and the project’s Safety Officer within 48 h of the study’s knowledge of SAE. Since adverse event reporting is not available for patients in the control arm, we will provide the board with quarterly reports comparing all emergency department visits, inpatient admissions and mortality among patients with dementia who are seen in clinics randomized to the intervention arm of the study and those seen in clinics randomized to the control arm of the study.

Ethics approval

The Institutional Review Board (IRB) for the NIA IMPACT Collaboratory, Advarra, reviewed and approved the study protocol on September 8, 2021. A waiver of consent was approved for use of Medicare claims data to conduct the analyses for aims 1 and 2 was approved. Clinician champions were provided a study information sheet at the start of the intervention (January 2022) with information about their participation and how to withdraw from the study. Any subsequent protocol modifications will be submitted to the Advarra IRB.



In their commentary on unpacking de-implementation, Norton and Chambers encouraged the field of implementation science to consider “critically important distinctions between the implementation of new, evidence-based interventions, and the de-implementation of currently delivered inappropriate interventions.” [20]. Although there is a strong rationale for the use of a clinician champion as a de-implementation strategy [24], few studies have employed them to address low-value care, although Colla and colleagues identified strategies that champions might employ such as clinician education and provider feedback as effective [34]. Santos and colleagues recently completed a systematic review of the effectiveness of a clinician champion when implementing an innovation into health care settings [35]. Only one of the 35 studies included in the review was focused on de-implementing a low-value care service, that of urinary catheters in pediatric patients. However, it is possible that the search strategy focus on implementation for this systematic review did not identify studies of de-implementation. This embedded pragmatic trial will add to the literature and expand our understanding of the effectiveness of a clinician champion as a strategy to de-implement care for which the potential for harm is greater than the potential for benefit: potentially inappropriate medications prescribed to people living with dementia.

This study will also allow health care systems and investigators to gain real-world experience in developing clinicians who can be champions of high-value care within their setting. Leaders in both participating ACOs have expressed an interest in spreading this intervention to all primary care clinic locations within their ACO and to other members of National Association of Accountable Care Organizations. Both findings from the trial and lessons learned from preparing clinician champions will be disseminated through publications in peer-reviewed publications, presentations at national conferences, and for interested stakeholders such as ACO leadership.


It is possible that clinician champions may leave or relocate their clinical practice during the study. We will guard against this be identifying a primary and secondary clinician champion within each clinic. Information shared by the clinician champions within their own clinical setting in the intervention arm of the study may be inadvertently shared with clinicians who provide care in clinics randomized to the control arm of the study. Finally, there may be clinics with a small sample of patients with dementia, which may adversely impact our ability to draw conclusions from the results.


Value champions who complete the study will be prepared to serve as mentors of clinician value champions within their own organizations and across other ACOs after the conclusion of the study. The clinician champion training is generic and can be applied to any low-value care service and the content of the curriculum, along with the project workbook, have been deliberately designed so that any health system might use them to train their own cohort of clinician champions in the future.

Availability of data and materials

The curriculum and materials to prepare clinician champions for the intervention are available at The datasets will be available upon request from the investigators.


  1. Delgado J, Bowman K, Clare L. Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007. BMJ Open. 2020;10(1):e029172.

    Article  Google Scholar 

  2. Ruangritchankul S, Peel NM, Hanjani LS, Gray LC. Drug related problems in older adults living with dementia. PLoS One. 2020;15(7):e0236830.

    Article  CAS  Google Scholar 

  3. Redston MR, Hilmer SN, McLachlan AJ, Clough AJ, Gnjidic D. Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: a systematic review. J Alzheimers Dis. 2018;61(4):1639–52.

    Article  Google Scholar 

  4. American Geriatrics Society. Ten things clinicians and patients should question. Philadelphia: Choosing Wisely, ABIM Foundation; 2013. updated April 23, 2015. Available from:

    Google Scholar 

  5. Mitchell SL, Mor V, Harrison J, McCarthy EP. Embedded pragmatic trials in dementia care: realizing the vision of the NIA IMPACT Collaboratory. J Am Geriatr Soc. 2020;68(Suppl 2):S1–7.

    PubMed  PubMed Central  Google Scholar 

  6. Gao USGAO. Antipsychotic Drug Use: HHS Has Initiatives to Reduce Use Among Older Adults in Nursing Homes, But Should Expand Efforts to Other Settings: Independently Published; 2019.

  7. Dionne PA, Vasiliadis HM, Latimer E, Berbiche D, Preville M. Economic impact of inappropriate benzodiazepine prescribing and related drug interactions among elderly persons. Psychiatr Serv. 2013;64(4):331–8.

    Article  Google Scholar 

  8. Hambling CE, Seidu SI, Davies MJ, Khunti K. Older people with type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabet Med. 2017;34(9):1219–27.

    Article  CAS  Google Scholar 

  9. Park S, Jung J, Burke RE, Larson EB. Trends in use of low-value Care in Traditional fee-for-Service Medicare and Medicare Advantage. JAMA Netw Open. 2021;4(3):e211762.

    Article  Google Scholar 

  10. Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SDS, Roberts HC. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 2021;21(1):258.

    Article  Google Scholar 

  11. Shafiee Hanjani L, Long D, Peel NM, Peeters G, Freeman CR, Hubbard RE. Interventions to optimise prescribing in older people with dementia: a systematic review. Drugs Aging. 2019;36(3):247–67.

    Article  Google Scholar 

  12. Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35(11):3323–32.

    Article  Google Scholar 

  13. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165.

    PubMed  Google Scholar 

  14. Almutairi H, Stafford A, Etherton-Beer C, Flicker L. Optimisation of medications used in residential aged care facilities: a systematic review and meta-analysis of randomised controlled trials. BMC Geriatr. 2020;20(1):236.

    Article  Google Scholar 

  15. Thio SL, Nam J, van Driel ML, Dirven T, Blom JW. Effects of discontinuation of chronic medication in primary care: a systematic review of deprescribing trials. Br J Gen Pract. 2018;68(675):e663–e72.

    Article  Google Scholar 

  16. Ulley J, Harrop D, Ali A, Alton S, Fowler DS. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatr. 2019;19(1):15.

    Article  Google Scholar 

  17. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.

    Article  Google Scholar 

  18. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA. 2018;320(18):1889–98.

    Article  Google Scholar 

  19. Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, et al. Deprescribing education vs usual care for patients with cognitive impairment and primary care clinicians: the OPTIMIZE pragmatic cluster randomized trial. JAMA Intern Med. 2022;182(5):534–42.

    Article  Google Scholar 

  20. Norton WE, Chambers DA. Unpacking the complexities of de-implementing inappropriate health interventions. Implement Sci. 2020;15(1):2.

    Article  Google Scholar 

  21. Miech EJ, Rattray NA, Flanagan ME, Damschroder L, Schmid AA, Damush TM. Inside help: an integrative review of champions in healthcare-related implementation. SAGE Open Med. 2018;6:2050312118773261.

    Article  Google Scholar 

  22. Wood K, Giannopoulos V, Louie E, Baillie A, Uribe G, Lee KS, et al. The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: a systematic review. Implement Res Pract. 2020;1:263348952095907.

    Article  Google Scholar 

  23. Damschroder LJ, Banaszak-Holl J, Kowalski CP, Forman J, Saint S, Krein SL. The role of the champion in infection prevention: results from a multisite qualitative study. Qual Saf Health Care. 2009;18(6):434–40.

    Article  CAS  Google Scholar 

  24. Stammen LA, Stalmeijer RE, Paternotte E, Oudkerk Pool A, Driessen EW, Scheele F, et al. Training physicians to provide high-value, cost-conscious care: a systematic review. JAMA. 2015;314(22):2384–400.

    Article  CAS  Google Scholar 

  25. Parchman ML, Palazzo LG, Mogk JM, Webbon JC, Demosthenes L, Vossenkemper E, et al. What strategies are used by clinician champions to reduce low-value care? SAGE Open Med. 2022;10:20503121211069855.

    Article  Google Scholar 

  26. Grodstein F, Chang C-H, Capuano AW, Power MC, Marquez DX, Barnes LL, et al. Identification of dementia in recent medicare claims data, compared with rigorous clinical assessments. J Gerontol: Ser A. 2021;77(6):1272–8.

    Article  Google Scholar 

  27. Sperber CM, Samarasinghe SR, Lomax GP. An upper and lower bound of the medication possession ratio. Patient Prefer Adherence. 2017;11:1469–78.

    Article  Google Scholar 

  28. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.

    Article  Google Scholar 

  29. Min L, Tinetti M, Langa KM, Ha J, Alexander N, Hoffman GJ. Measurement of fall injury with health care system data and assessment of inclusiveness and validity of measurement models. JAMA Netw Open. 2019;2(8):e199679.

    Article  Google Scholar 

  30. Mettert K, Lewis C, Dorsey C, Halko H, Weiner B. Measuring implementation outcomes: an updated systematic review of measures’ psychometric properties. Implement Res Pract. 2020;1:263348952093664.

    Article  Google Scholar 

  31. Lewis CC, Fischer S, Weiner BJ, Stanick C, Kim M, Martinez RG. Outcomes for implementation science: an enhanced systematic review of instruments using evidence-based rating criteria. Implement Sci. 2015;10:155.

    Article  Google Scholar 

  32. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Admin Pol Ment Health. 2011;38(2):65–76.

    Article  Google Scholar 

  33. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis:striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):1609406917733847.

    Article  Google Scholar 

  34. Colla CH, Mainor AJ, Hargreaves C, Sequist T, Morden N. Interventions aimed at reducing use of low-value health services: a systematic review. Med Care Res Rev. 2017;74(5):507–50.

    Article  Google Scholar 

  35. Santos WJ, Graham ID, Lalonde M, Demery Varin M, Squires JE. The effectiveness of champions in implementing innovations in health care: a systematic review. Implement Sci Commun. 2022;3(1):80.

    Article  Google Scholar 

Download references


We sincerely thank the leadership and clinicians at the two accountable care organizations who are participating in this study.


The work was funded by the National Institutes on Aging (NIA) Imbedded Pragmatic Alzheimer's Disease and AD-Related Dementias Clinical Trials Collaboratory (NIA IMPACT Collaboratory), Grant/Award Number: 3U54AG063546-03 (Contact: Vince Mor, PhD, Brown University School of Public Health. The content is solely the responsibilities of the authors and does not reflect the official views of the National Institutes of Health. 

Author information

Authors and Affiliations



MP, JP, and GR contributed to the study concept and design, selection of methods, analysis plan, and preparation of manuscript. MP and JP contributed to the acquisition of sites and subjects and/or data. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Michael L. Parchman.

Ethics declarations

Ethics approval and consent to participate

The Advarra Institutional Review Board (IRB) reviewed and approved the study protocol on September 8, 2021. A waiver of consent was approved for use of Medicare claims data. Clinician champions are provided a study information sheet with information about their participation and how to withdraw from the study. Any subsequent protocol modifications will be submitted to the Advarra IRB.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Parchman, M.L., Perloff, J. & Ritter, G. Can clinician champions reduce potentially inappropriate medications in people living with dementia? Study protocol for a cluster randomized trial. Implementation Sci 17, 63 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • De-implementation
  • De-prescribing
  • Low-value
  • Overuse
  • Dementia
  • Implementation science